Pharma fraud

Another day, another billion dollar pharma company fraud settlement with felony guilty pleas. In my NEJM Perspective (now online), I argue that the industry is treating these fines like a cost of doing business, without sufficient deterrent value. Options include:

  • Criminal prosecution of individuals in addition to the companies;
  • Enhanced whistleblower protections;
  • Recouping a larger percentage of the ill-gotten gains; and
  • Regulating the industry on a level playing field instead of layers of “corporate integrity agreements”

The latest settlement with GSK (J&J should announce soon) promises to recoup fraud-related bonuses from future executives and to stop paying drug reps based on off-label sales effectiveness.  GSK also pled guilty to hiding important safety data on Avandia.


Share on twitter
Share on facebook
Share on linkedin
Share on reddit
Share on email

Hidden information below


* indicates required
Email Format